

**BAXTER INTERNATIONAL INC.**  
**Net Sales**  
**Periods Ending December 31, 2008 and 2007**  
**(unaudited)**  
**(\$ in millions)**

	Q4 2008	Q4 2007	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2008	YTD 2007	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience<sup>1</sup></b>								
United States	\$647	\$579	12%	12%	\$2,401	\$2,151	12%	12%
International	712	630	13%	23%	2,907	2,419	20%	14%
<b>Total</b>	<b>\$1,359</b>	<b>\$1,209</b>	<b>12%</b>	<b>17%</b>	<b>\$5,308</b>	<b>\$4,570</b>	<b>16%</b>	<b>13%</b>
<b>Medication Delivery</b>								
United States	\$590	\$564	5%	5%	\$2,145	\$2,142	0%	0%
International	584	591	(1%)	8%	2,415	2,089	16%	10%
<b>Total</b>	<b>\$1,174</b>	<b>\$1,155</b>	<b>2%</b>	<b>7%</b>	<b>\$4,560</b>	<b>\$4,231</b>	<b>8%</b>	<b>5%</b>
<b>Renal</b>								
United States	\$98	\$100	(2%)	(2%)	\$388	\$388	0%	0%
International	459	501	(8%)	(4%)	1,918	1,851	4%	(2%)
<b>Total</b>	<b>\$557</b>	<b>\$601</b>	<b>(7%)</b>	<b>(3%)</b>	<b>\$2,306</b>	<b>\$2,239</b>	<b>3%</b>	<b>(2%)</b>
<b>Baxter excluding Transfusion Therapies</b>								
United States	\$1,335	\$1,243	7%	7%	\$4,934	\$4,681	5%	5%
International	1,755	1,722	2%	10%	7,240	6,359	14%	8%
<b>Total</b>	<b>\$3,090</b>	<b>\$2,965</b>	<b>4%</b>	<b>9%</b>	<b>\$12,174</b>	<b>\$11,040</b>	<b>10%</b>	<b>7%</b>
<b>Transfusion Therapies<sup>1</sup></b>								
United States	\$17	\$31	(45%)	(45%)	\$110	\$139	(21%)	(21%)
International	24	13	85%	54%	64	84	(24%)	(32%)
<b>Total</b>	<b>\$41</b>	<b>\$44</b>	<b>(7%)</b>	<b>(16%)</b>	<b>\$174</b>	<b>\$223</b>	<b>(22%)</b>	<b>(25%)</b>
<b>Baxter International Inc.</b>								
United States	\$1,352	\$1,274	6%	6%	\$5,044	\$4,820	5%	5%
International	1,779	1,735	3%	10%	7,304	6,443	13%	7%
<b>Total</b>	<b>\$3,131</b>	<b>\$3,009</b>	<b>4%</b>	<b>9%</b>	<b>\$12,348</b>	<b>\$11,263</b>	<b>10%</b>	<b>6%</b>

<sup>1</sup> The results of operations of the Transfusion Therapies (TT) business were previously reported in the BioScience business. The TT business was sold on February 28, 2007. The TT totals above include sales of TT products through the date of divestiture, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.